Closing Session
Saturday, May 25, 2019 |
2:00 PM - 2:40 PM |
Great Room |
Speaker
Prof Saye Khoo
Professor
University Of Liverpool
Q & A Panel
2:00 PM - 2:30 PMBiography
Professor Saye Khoo, MD, PhD, is Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the Institute of Translational Medicine at the University of Liverpool.
His research focuses on the pharmacology of HIV treatment failure and how therapy may be improved through individualised care through understanding of why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics and drug interactions), and identify vulnerable groups who are at particular risk of failure, or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population-based modelling approaches.
Associate Professor James McMahon
Head of Clinical Research Unit
Alfred Health
Q & A Panel
2:00 PM - 2:30 PMBiography
Dr McMahon is an Infectious Diseases physician and Head of Clinical Research at the Alfred Hospital, an Infectious Diseases physician at Monash Medical Centre and Chairs the ASHM ARV Guidelines Committee. His main research interests are in the field of HIV Cure including clinical trials to image tissue sites of persistent HIV and clinical trials of interventions to target the HIV reservoir.
Dr Janine Trevillyan
Infectious Diseases Physician And Senior Research Fellow
University of California, Los Angeles
Q & A Panel
2:00 PM - 2:30 PMBiography
Dr Janine Trevillyan is an infectious diseases physician and clinical researcher whose work focuses on understanding and preventing HIV-associated comorbidities. She completed her clinical training at the Alfred and Austin Hospitals in Melbourne, Australia and a PhD through Monash University in 2015. In 2016 she commenced a postdoctoral fellowship at the University of California, Los Angeles, Clinical AIDS Research and Education Centre where she is currently based. She’s an active member of the AIDS Clinical Trials Group (ACTG) and is currently investigating non-pharmacological methods of reducing cardiovascular risk in people living with HIV.